Tango Therapeutics Inc
$ 12.67
0.48%
12 Feb - close price
- Market Cap 1,706,359,000 USD
- Current Price $ 12.67
- High / Low $ 13.10 / 12.25
- Stock P/E N/A
- Book Value 1.43
- EPS -0.91
- Next Earning Report 2026-02-26
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.24 %
- ROE -0.52 %
- 52 Week High 13.48
- 52 Week Low 1.03
About
Tango Therapeutics Inc. is a clinical-stage biotechnology company focused on harnessing the power of targeted therapies to treat cancer. The company is pioneering the development of novel therapeutics designed to exploit vulnerabilities in cancer cells, particularly through proprietary insights into synthetic lethality. With a robust pipeline of innovative drug candidates, Tango is positioned to make significant advancements in precision oncology. The company's commitment to transforming cancer treatment is underscored by its collaborations with leading research institutions, enhancing its scientific capabilities and accelerating its product development efforts.
Analyst Target Price
$15.25
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-04 | 2025-08-05 | 2025-05-06 | 2025-03-17 | 2024-11-06 | 2024-08-07 | 2024-05-08 | 2024-03-18 | 2023-11-08 | 2023-08-07 | 2023-05-09 | 2023-03-27 |
| Reported EPS | -0.14 | -0.35 | -0.36 | -0.34 | -0.27 | -0.24 | -0.35 | -0.32 | -0.23 | -0.23 | -0.32 | -0.33 |
| Estimated EPS | -0.07 | -0.35 | -0.3459 | -0.3428 | -0.37 | -0.34 | -0.31 | -0.28 | -0.34 | -0.34 | -0.35 | -0.35 |
| Surprise | -0.07 | 0 | -0.0141 | 0.0028 | 0.1 | 0.1 | -0.04 | -0.04 | 0.11 | 0.11 | 0.03 | 0.02 |
| Surprise Percentage | -100% | 0% | -4.0763% | 0.8168% | 27.027% | 29.4118% | -12.9032% | -14.2857% | 32.3529% | 32.3529% | 8.5714% | 5.7143% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-26 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.31 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TNGX
2026-02-09 19:28:07
Eight brokerages have given Tango Therapeutics (NASDAQ:TNGX) an average rating of "Moderate Buy," with a 12-month average price target of $14.80. The stock recently opened at $12.51, nearing its 52-week high, and has a market capitalization of $1.68 billion. Insider transactions show recent sales by Adam Crystal and Barbara Weber, while institutional investors have adjusted their holdings.
2026-02-07 13:29:15
Guggenheim analyst Michael Schmidt reiterated a Buy rating for Tango Therapeutics (TNGX) with an $18.00 price target, following the company's Q3 earnings report showing significant revenue growth and net profit. Despite increased insider selling, the overall analyst consensus remains a Strong Buy.
2026-02-06 19:28:07
Guggenheim has raised its price target for Tango Therapeutics (NASDAQ:TNGX) from $12.00 to $18.00, maintaining a "buy" rating and suggesting a potential 42% upside. The company surpassed earnings and revenue estimates in its last quarter, though it remains unprofitable. Insider sales totaling approximately $726,871 have occurred in the last 90 days, while institutional investors hold nearly 79% of the stock.
2026-02-05 21:27:41
Tango Therapeutics (NASDAQ:TNGX) insider Adam Crystal sold 18,452 shares of the company's stock for approximately $226,222 on February 3rd, reducing his stake by nearly 9%. Despite this insider selling, TNGX recently outperformed analyst revenue and EPS estimates, though it remains unprofitable. The stock currently holds a "Moderate Buy" consensus rating from analysts, with a mean price target around $13.60.
2026-02-05 20:57:48
Tango Therapeutics Director Barbara Weber sold 30,519 shares of TNGX stock for approximately $374,163 on February 3rd, reducing her ownership by 1.84%. The company's stock traded down 1.8% to $12.32, with a market capitalization of $1.66 billion. Tango Therapeutics recently beat quarterly EPS and revenue estimates, and analysts maintain a "Moderate Buy" rating with an average price target of $13.60.
2026-02-05 01:00:09
Tango Therapeutics director, Weber Barbara, sold 30,519 shares of TNGX common stock for approximately $374,293 on February 3, 2026. This transaction follows her acquisition of 37,522 shares and 222,132 stock options a day earlier. The company also announced a $100 million at-the-market stock offering and several leadership changes, including Malte Peters becoming the new CEO and Barbara Weber transitioning to Executive Chair.
